SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-176619
Filing Date
2022-06-17
Accepted
2022-06-17 17:00:02
Documents
12
Period of Report
2022-06-13
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K d535099d8k.htm   iXBRL 8-K 24400
  Complete submission text file 0001193125-22-176619.txt   146030

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA labp-20220613.xsd EX-101.SCH 2870
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE labp-20220613_lab.xml EX-101.LAB 17980
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE labp-20220613_pre.xml EX-101.PRE 11268
6 EXTRACTED XBRL INSTANCE DOCUMENT d535099d8k_htm.xml XML 3336
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

IRS No.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 221024762
SIC: 2834 Pharmaceutical Preparations